Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

1986 • 698 citations

Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.

1987 • 565 citations

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

1986 • 459 citations

Lymphokine-activated killer cells. Analysis of progenitors and effectors.

1986 • 403 citations

Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.

1984 • 310 citations

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

1985 • 293 citations

Monoclonal antibodies which distinguish between human NK cells and cytotoxic T lymphocytes

1980 • 189 citations

Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

1986 • 166 citations

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1988 • 159 citations

Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1

1988 • 139 citations

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.

1988 • 138 citations

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.

1987 • 119 citations

Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.

1986 • 107 citations

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

1988 • 79 citations

Systemic administration of interleukin-2 in humans.

1984 • 78 citations

Potential Uses of Interleukin 2 in Cancer Therapy

1986 • 22 citations